Exchange: NASDAQ·Updated 04:38 PM EDT

IMVT News

News
all
press releases
Immunovant Q1 2027 Earnings Call: Complete Transcript
Immunovant (NASDAQ:IMVT) held its first-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and financialread more...
Benzinga
Immunovant Q1 2027 Earnings Call: Complete Transcript
Immunovant (NASDAQ:IMVT) held its first-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and financialread more...
Benzinga
More News
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law FirmPR NewswireNEW YORK, Oct. 12, 2026NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain...
PR Newswire
IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Immunovant, Inc. (Immunovant or the Company) (NASDAQ: IMVT) for violations of the securities laws.INVESTIGATION DETAILS: The investigation focuses...
Business Wire
IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class
Immunovant is developing IMVT-1402 in an ongoing mid-stage study in Sjögren’s disease, which works the same way as Argenx’s efgartigimod.
Stocktwits
Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT)
Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT) Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT)PR NewswireNEW YORK, Sept. 25, 2026 Immunovant stock fell roughly 6% to a...
PR Newswire
IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down
Immunovant's IMVT-1402 misses its primary CLE goal, prompting the company to halt the program despite positive trends and a favorable safety profile.
Zacks
Immunovant Ends Autoimmune Skin Disorder Program
Immunovant halts IMVT-1402 CLE trial after missing primary endpoints, driving IMVT and Roivant shares down in premarket trading.read more...
Benzinga
Immunovant Pulls Plug On Lupus Program After Study Misses Primary Goal — IMVT Stock Heads For Over 3-Month Lows
Immunovant is discontinuing development of IMVT-1402 in cutaneous lupus but will continue to develop the therapy for several other autoimmune diseases.
Stocktwits
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm PR Newswire NEW YORK, Aug. 19, 2026 NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether...
PR Newswire
Immunovant (IMVT) Q1 2027 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets

Advertisement|Remove ads.